Anti-müllerian hormone is found raised in polycystic ovarian syndrome

Polycystic ovarian syndrome (PCOS) is the most common form of chronic anovulation associated with androgen excess. Large scale studies have observed a prevalence rate of PCOS 5% to 10% among reproductive-age women.1,2 Currently, there are 3 widely accepted sets of criteria for diagnosis of PCOS.3,4 After excluding other causes of hyperandrogenism, National Institute of Health (NIH) criteria (1990) requires I) evidence of hyperandrogenism (clinical or biochemical) and II) evidence of anovulation or oligo-ovulation. Rotterdam criteria (2003) added the presence of polycystic ovarian morphology (2 out of 3 need to be present). The Androgen Excess and PCOS society criteria (2006) considered polycystic ovarian morphology as an alternative evidence of ovarian dysfunction. However, the diagnosis of PCOS is often a diagnostic dilemma, as because not all patients express hyperandrogenism. A substantial number of women may have polycystic appearing ovaries American Research Journal of Endocrinology Volume 1, Issue 1, pp:1-8